NASDAQ: NMRA - Neumora Therapeutics, Inc. Common Stock

Rentabilität für sechs Monate: +15.61%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Neumora Therapeutics, Inc. Common Stock


Über das Unternehmen Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

weitere details
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. The company was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

IPO date 2023-09-14
ISIN US6409791000
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://neumoratx.com
Цена ао 11.85
Preisänderung pro Tag: -0.0882% (11.34)
Preisänderung pro Woche: +4.42% (10.85)
Preisänderung pro Monat: +16.09% (9.76)
Preisänderung über 3 Monate: -12.31% (12.92)
Preisänderung über sechs Monate: +15.61% (9.8)
Preisänderung pro Jahr: -33.9% (17.14)
Preisänderung über 3 Jahre: 0% (11.33)
Preisänderung über 5 Jahre: 0% (11.33)
Preisänderung über 10 Jahre: 0% (11.33)
Preisänderung seit Jahresbeginn: -3.41% (11.73)

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 5.77 2
P/E 0 0
EV/EBITDA -12.47 0
Gesamt: 2.25

Effizienz

Name Bedeutung Grad
ROA, % -47.55 0
ROE, % -50.3 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0279 10
Gesamt: 9.4

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 96.57 9
Rentabilität EPS, % 127.36 10
Gesamt: 7.8

Institutionen Volumen Aktie, %
Softbank Group Corporation 7646916 4.81
FMR, LLC 6373129 4.01
MIC Capital Management UK LLP 4460700 2.81
ICONIQ Capital, LLC 3398628 2.14
Wellcome Trust Ltd (the) As Trustee Of The Wellcome Trust 3309123 2.08
Artal Group S.A. 2552702 1.61
EcoR1 Capital, LLC 2071450 1.3
Avidity Partners Management, LP 1990632 1.25
Johnson & Johnson 1849445 1.16
Citadel Advisors Llc 1843291 1.16

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares U.S. Pharmaceuticals ETF 0.41562 6.09 1.97922
iShares Russell 2000 Growth ETF 0.08025 38.04 0.6026
iShares Morningstar Small-Cap ETF 0.01976 391.25 1.60498
iShares Morningstar Small-Cap ETF 0.01976 30.1 1.60498
iShares Russell 3000 ETF 0.00212 24.83 1.43482



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Paul L. Berns Co-Founder & Executive Chairman 1.65M 1967 (58 Jahre)
Mr. Henry O. Gosebruch President, CEO & Director 3.33M 1973 (52 Jahr)
Ms. Carol Suh Co-Founder & COO N/A 1990 (35 Jahre)
Dr. Rajesh Manchanda Ph.D. Chief Technical Operations Officer N/A 1966 (59 Jahre)
Mr. Nicholas Brandon Ph.D. Chief Scientific Officer N/A 1974 (51 Jahr)
Mr. Jason G. Duncan Chief Legal Officer 315k 1974 (51 Jahr)
Mr. Michael Lee Milligan Principal Accounting Officer N/A
Mr. Robert Lenz M.D., Ph.D. Head of Research & Development 770.29k 1971 (54 Jahr)
Dr. Joshua Pinto Ph.D. Chief Financial Officer 876.64k 1985 (40 Jahre)
Dr. Robert Michael Poole FACP, M.D. Co-Founder & Advisor 1957 (68 Jahre)

Adresse: United States, Watertown. MA, 490 Arsenal Way - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://neumoratx.com